The deal gains BioMarin a novel oral therapy for HPP, potentially expanding into a larger rare disease market. The all-cash structure and expected Q3 close limit balance-sheet risk. Watch for the closing, any regulatory updates on ALE-1, and updated 2026 guidance. The spin-out structure means no employee integration risk.
Price Chart
Executive Summary
BioMarin (BMRN) entered into a definitive Share Purchase Agreement to acquire Alesta Therapeutics for $275 million upfront in cash, with up to $215 million in additional milestone-based payments, for a total potential consideration of up to $490 million. Alesta's lead asset is ALE-1, an oral small-molecule in a Phase 1/2a trial for hypophosphatasia (HPP). The deal is expected to close in Q3 2026, funded from cash on hand.
Key Financial Metrics
Key Facts
- BioMarin to acquire Alesta Therapeutics for $275M upfront cash, subject to customary post-closing purchase price adjustment.
- Up to $215M in additional milestone payments tied to development and regulatory achievements for ALE-1.
- ALE-1 is an orally active small molecule in Phase 1/2a for hypophosphatasia (HPP), a rare genetic bone disease with over 9,000 diagnosed patients in the US.
- Alesta will spin out all non-ALE1 assets to a new entity (Anaheim SpinCo) prior to closing; no Alesta employees will join BioMarin.
- Transaction expected to close in Q3 2026, funded with BioMarin's cash on hand.
- Excluding the upfront consideration, the deal is expected to be modestly dilutive to 2026 financial results.
- BioMarin plans to update full-year 2026 guidance after closing.
Financial Impact
Up to $490 million total potential consideration ($275M upfront + up to $215M milestones), all in cash. BioMarin intends to use cash on hand.
Risk Factors
- Clinical and regulatory uncertainty: ALE-1 is still in Phase 1/2a; failure or delay would impair milestone value.
- Milestone payments are contingent on future events; if milestones are not achieved, total consideration will be lower.
- The spin-out of non-ALE1 assets must be completed before close; any complication could delay closing.
- The upfront $275M outlay will reduce cash reserves, and the deal is expected to be modestly dilutive to 2026 EPS.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-354780 |
| Document: d172628d8k.htm | 0001193125-26-354780 |
| Document: d172628dex991.htm | 0001193125-26-354780 |
| Document: 0001193125-26-354780-index-headers.html | 0001193125-26-354780 |
| Document: 0001193125-26-354780-index.html | 0001193125-26-354780 |
| Document: 0001193125-26-354780.txt | 0001193125-26-354780 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 17d ago | 8-K | $64.45 $63.94 | ▼ −0.79% | ▼ −1.61% | $57.18 (−11.28%) |
Sep 14, 2026 18d ago | 8-K | $66.41 $64.06 | ▼ −3.54% | ▼ −3.65% | $57.18 (−13.90%) |
Sep 1, 2026 4w ago | 8-K | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.18 (−11.81%) |
Sep 1, 2026 4w ago | Press Release | $64.84 $64.41 | ▼ −0.66% | ▼ −0.74% | $57.18 (−11.81%) |
Aug 31, 2026 4w ago | 8-K | $65.23 $64.63 | ▼ −0.92% | ▼ −0.78% | $57.18 (−12.34%) |
Aug 18, 2026 6w ago | 8-K | $66.99 $66.12 | ▼ −1.30% | ▼ −1.10% | $57.18 (−14.64%) |
Jun 4, 2026 17w ago | 8-K | $56.77 $55.95 | ▼ −1.44% | ▼ −2.01% | $57.18 (+0.72%) |
Apr 27, 2026 22w ago | 8-K | $53.62 $55.42 | ▲ +3.36% | ▲ +2.96% | $57.18 (+6.63%) |
Apr 21, 2026 23w ago | DEFA14A | $54.16 $53.24 | ▼ −1.71% | ▼ −1.76% | $57.18 (+5.57%) |
Feb 28, 2026 30w ago | Institutional Cluster | $59.71 $60.65 | ▲ +1.57% | ▲ +2.78% | $57.18 (−4.24%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access